TMO Form 4: Casper executes option exercise and 10b5-1 sales on Aug 22, 2025
Rhea-AI Filing Summary
Marc N. Casper, Chairman & CEO of Thermo Fisher Scientific (TMO), reported option exercise and offsetting open-market sales executed under a 10b5-1 plan. He exercised a stock option to acquire 10,000 shares at an exercise price of $253.99 on 08/22/2025. On the same date he sold a total of 10,000 shares in multiple transactions at weighted-average prices within three reported ranges: approximately $500.00–$500.98, $501.05–$501.99, and $502.02–$502.37. Following these transactions his direct beneficial ownership is reported as 115,173.623 shares, and he also reports indirect holdings through trusts and entities totaling additional positions. The sales were made pursuant to a Rule 10b5-1 trading plan adopted April 28, 2025.
Positive
- Exercise of options reported with price: 10,000 shares exercised at $253.99, clearly disclosed
- Pre-scheduled trading: Sales executed under a Rule 10b5-1 plan adopted April 28, 2025
- Detailed sale pricing: Weighted-average price ranges provided for multiple sale tranches
- Substantial insider ownership retained: Direct beneficial ownership of 115,173.623 shares plus indirect holdings
Negative
- Large open-market sales: 10,000 shares sold on 08/22/2025 at prices around $500–$502, representing insider liquidity
- Potential perception risk: Same-day exercise and sale may be viewed by some investors as monetization of equity
Insights
TL;DR: CEO exercised options and sold an equal number of shares under a 10b5-1 plan, leaving substantial direct and indirect holdings.
Marc Casper exercised a stock option for 10,000 shares at $253.99 and sold 10,000 shares the same day at market-weighted prices near $500–$502. The net share count reported shows meaningful insider ownership of 115,173.623 direct shares plus additional indirect holdings via trusts and entities. The use of a 10b5-1 plan indicates pre-scheduled trades rather than ad-hoc dispositions. For investors, this is a routine management liquidity event rather than an operational signal; the transactions were structured to be orderly and pre-authorized.
TL;DR: Transactions comply with Rule 10b5-1; disclosure provides weighted-price ranges and disclaimers on indirect ownership.
The Form 4 clearly discloses that the sales were effected under a 10b5-1 plan adopted April 28, 2025, and provides weighted-average price ranges for multiple sale tranches. The filer disclaims beneficial ownership for certain indirect holdings except for pecuniary interest, and the signature is provided by an attorney-in-fact. Documentation appears complete and transparent for an insider liquidity event, meeting standard governance disclosure expectations.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $253.99 | $2.54M |
| Sale | Common Stock | 5,823 | $500.40 | $2.91M |
| Sale | Common Stock | 3,579 | $501.65 | $1.80M |
| Sale | Common Stock | 598 | $502.26 | $300K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $500.001 to $500.98, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $501.05 to $501.99, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.02 to $502.37, inclusive. The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. The option vested in four equal installments on February 26, 2020, 2021, 2022, and 2023.
